Profile

Hello Cami, I don't have a ton of experience to share with you as we have only just moved to outpatient administration of tarla within the last 4-6 weeks. We have our third patient scheduled for outpatient administration in the next week or so. We are planning a likely "phased in" approach whereby we ...

Thanks, Kevin, for bringing up this topic. I have attended TTLC virtually in the past and do agree that it is helpful for current clinical debates and learning about updates on targeted therapies in the pipeline. Shameless plug in general, I have been a member of IASLC for the past 5 years and on ...

Replying to Cami--I last asked on 12/9/25 and got the response below. I am sure that I am REALLY annoying to them because I send this guy an email about once every 2 months. I can email him again if it would be helpful: Dear Stefanie, At this stage, the details are still under discussion, so I am not ...

Hi Kevin, I saw your message yesterday and I emailed the contact I have at Dizal. This was the exact response I received this morning (see below). Frustrating, I know! Dear Stefanie, We appreciate your follow-up. Right now, we are actively working to establish the necessary infrastructure and processes ...

Hello Thoracic Team, Do you hold RET inhibitors (given their off-target VEGFR1 and VEGFR3 inhibition) for patients requiring dental surgery with manipulation around the jaw bone or only if on concurrent antiresorptive therapy with bisphosphonates or denosumab? I am seeing a low risk of ONJ in the literature ...